Treatment of Hypertension with Propranolol
When used in the treatment of hypertension propranolol is at least of similar potency to bethanidine, guanethidine, and methyldopa. Propranolol does not produce postural or exercise hypotension and it seems that it is often more acceptable to patients than conventional drugs. It usually produces the...
Gespeichert in:
Veröffentlicht in: | BMJ 1969-01, Vol.1 (5635), p.7-16 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 16 |
---|---|
container_issue | 5635 |
container_start_page | 7 |
container_title | BMJ |
container_volume | 1 |
creator | Prichard, B. N. C. Gillam, P. M. S. |
description | When used in the treatment of hypertension propranolol is at least of similar potency to bethanidine, guanethidine, and methyldopa. Propranolol does not produce postural or exercise hypotension and it seems that it is often more acceptable to patients than conventional drugs. It usually produces the best control of the supine blood pressure. A series of 109 hypertensive patients was treated with propranolol; in nine the drug was withdrawn. In 92 of the patients a supine or standing blood pressure of 100 mm. Hg or less was achieved. Eighty of the patients had previously been treated with other potent drugs, and close comparisons and prolonged follow-up in 17 patients showed that diastolic pressures of 100 mm. Hg or less were achieved in more patients after propranolol than with guanethidine, bethanidine, or methyldopa. Sensitivity to propranolol varies widely, and dosage should be increased gradually. The hypotensive effect often takes six to eight weeks to reach its maximum. Propranolol reduces cardiac output but may also act by reducing the cardiac component of pressor stimuli; as a result the baroreceptors gradually regulate the blood pressure at a lower level. It is contraindicated in patients with obstructive airways disease or in uncompensated heart failure. |
doi_str_mv | 10.1136/bmj.1.5635.7 |
format | Article |
fullrecord | <record><control><sourceid>jstor_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1981816</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>20395359</jstor_id><sourcerecordid>20395359</sourcerecordid><originalsourceid>FETCH-LOGICAL-b499t-26de9d12c2bd6c57fddaee222d17bd43464743b6dbf14c5863cb80564a3970373</originalsourceid><addsrcrecordid>eNp9kM9LwzAYhoMoc8zdvAoDD4LY2S8_m4sgw6kg6mGKt5A2qevcmpl06v57WzqmXjyF8Dy838uL0CHEQwDCz9PFbAhDxgkbih3UBcqTiCWE7KJuHMciAkrFPuqHMKu_mIhEctpBHSY4SKBddDrxVlcLW1YDlw9u1kvrK1uGwpWDz6KaDh69W3pdurmbH6C9XM-D7W_eHnoaX01GN9Hdw_Xt6PIuSqmUVYS5sdIAznBqeMZEboy2FmNsQKSGEsqpoCTlJs2BZizhJEuTmHGqiRQxEaSHLtrc5SpdWJPV3byeq6UvFtqvldOF-kvKYqpe3YcCmUACvA443gR4976yoVIzt_Jl3VmBEBwz4Elz5qy1Mu9C8DbfXoBYNduqelsFqtlWNfrR71ZbebPkD5-FyvktxjGRjDBZ86jlRajs15Zr_6a4IIKp--eRehk_3strgRWr_ZPWb1r82-wb41WZyg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1776251687</pqid></control><display><type>article</type><title>Treatment of Hypertension with Propranolol</title><source>MEDLINE</source><source>JSTOR Archive Collection A-Z Listing</source><source>PubMed Central</source><creator>Prichard, B. N. C. ; Gillam, P. M. S.</creator><creatorcontrib>Prichard, B. N. C. ; Gillam, P. M. S.</creatorcontrib><description>When used in the treatment of hypertension propranolol is at least of similar potency to bethanidine, guanethidine, and methyldopa. Propranolol does not produce postural or exercise hypotension and it seems that it is often more acceptable to patients than conventional drugs. It usually produces the best control of the supine blood pressure. A series of 109 hypertensive patients was treated with propranolol; in nine the drug was withdrawn. In 92 of the patients a supine or standing blood pressure of 100 mm. Hg or less was achieved. Eighty of the patients had previously been treated with other potent drugs, and close comparisons and prolonged follow-up in 17 patients showed that diastolic pressures of 100 mm. Hg or less were achieved in more patients after propranolol than with guanethidine, bethanidine, or methyldopa. Sensitivity to propranolol varies widely, and dosage should be increased gradually. The hypotensive effect often takes six to eight weeks to reach its maximum. Propranolol reduces cardiac output but may also act by reducing the cardiac component of pressor stimuli; as a result the baroreceptors gradually regulate the blood pressure at a lower level. It is contraindicated in patients with obstructive airways disease or in uncompensated heart failure.</description><identifier>ISSN: 0007-1447</identifier><identifier>ISSN: 0959-8138</identifier><identifier>EISSN: 1468-5833</identifier><identifier>DOI: 10.1136/bmj.1.5635.7</identifier><identifier>PMID: 5761914</identifier><language>eng</language><publisher>England: British Medical Journal Publishing Group</publisher><subject>Average age ; Blood pressure ; Blood Pressure - drug effects ; Cardiac Output - drug effects ; Cardiac output determination ; Diuretics ; Dosage ; Female ; Guanethidine - therapeutic use ; Guanidines - therapeutic use ; Humans ; Hypertension ; Hypertension - drug therapy ; Hypotension - chemically induced ; Left ventricular hypertrophy ; Male ; Methyldopa - therapeutic use ; Middle Aged ; Papers and Originals ; Physical Exertion ; Physicians ; Placebos ; Posture ; Pressoreceptors - physiology ; Pressure pulses ; Propranolol - administration & dosage ; Propranolol - adverse effects ; Propranolol - therapeutic use ; Valsalva Maneuver</subject><ispartof>BMJ, 1969-01, Vol.1 (5635), p.7-16</ispartof><rights>Copyright 1969 British Medical Journal</rights><rights>Copyright BMJ Publishing Group LTD Jan 4, 1969</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b499t-26de9d12c2bd6c57fddaee222d17bd43464743b6dbf14c5863cb80564a3970373</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/20395359$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/20395359$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>230,314,727,780,784,803,885,27924,27925,53791,53793,58017,58250</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/5761914$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Prichard, B. N. C.</creatorcontrib><creatorcontrib>Gillam, P. M. S.</creatorcontrib><title>Treatment of Hypertension with Propranolol</title><title>BMJ</title><addtitle>Br Med J</addtitle><description>When used in the treatment of hypertension propranolol is at least of similar potency to bethanidine, guanethidine, and methyldopa. Propranolol does not produce postural or exercise hypotension and it seems that it is often more acceptable to patients than conventional drugs. It usually produces the best control of the supine blood pressure. A series of 109 hypertensive patients was treated with propranolol; in nine the drug was withdrawn. In 92 of the patients a supine or standing blood pressure of 100 mm. Hg or less was achieved. Eighty of the patients had previously been treated with other potent drugs, and close comparisons and prolonged follow-up in 17 patients showed that diastolic pressures of 100 mm. Hg or less were achieved in more patients after propranolol than with guanethidine, bethanidine, or methyldopa. Sensitivity to propranolol varies widely, and dosage should be increased gradually. The hypotensive effect often takes six to eight weeks to reach its maximum. Propranolol reduces cardiac output but may also act by reducing the cardiac component of pressor stimuli; as a result the baroreceptors gradually regulate the blood pressure at a lower level. It is contraindicated in patients with obstructive airways disease or in uncompensated heart failure.</description><subject>Average age</subject><subject>Blood pressure</subject><subject>Blood Pressure - drug effects</subject><subject>Cardiac Output - drug effects</subject><subject>Cardiac output determination</subject><subject>Diuretics</subject><subject>Dosage</subject><subject>Female</subject><subject>Guanethidine - therapeutic use</subject><subject>Guanidines - therapeutic use</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Hypertension - drug therapy</subject><subject>Hypotension - chemically induced</subject><subject>Left ventricular hypertrophy</subject><subject>Male</subject><subject>Methyldopa - therapeutic use</subject><subject>Middle Aged</subject><subject>Papers and Originals</subject><subject>Physical Exertion</subject><subject>Physicians</subject><subject>Placebos</subject><subject>Posture</subject><subject>Pressoreceptors - physiology</subject><subject>Pressure pulses</subject><subject>Propranolol - administration & dosage</subject><subject>Propranolol - adverse effects</subject><subject>Propranolol - therapeutic use</subject><subject>Valsalva Maneuver</subject><issn>0007-1447</issn><issn>0959-8138</issn><issn>1468-5833</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1969</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kM9LwzAYhoMoc8zdvAoDD4LY2S8_m4sgw6kg6mGKt5A2qevcmpl06v57WzqmXjyF8Dy838uL0CHEQwDCz9PFbAhDxgkbih3UBcqTiCWE7KJuHMciAkrFPuqHMKu_mIhEctpBHSY4SKBddDrxVlcLW1YDlw9u1kvrK1uGwpWDz6KaDh69W3pdurmbH6C9XM-D7W_eHnoaX01GN9Hdw_Xt6PIuSqmUVYS5sdIAznBqeMZEboy2FmNsQKSGEsqpoCTlJs2BZizhJEuTmHGqiRQxEaSHLtrc5SpdWJPV3byeq6UvFtqvldOF-kvKYqpe3YcCmUACvA443gR4976yoVIzt_Jl3VmBEBwz4Elz5qy1Mu9C8DbfXoBYNduqelsFqtlWNfrR71ZbebPkD5-FyvktxjGRjDBZ86jlRajs15Zr_6a4IIKp--eRehk_3strgRWr_ZPWb1r82-wb41WZyg</recordid><startdate>19690104</startdate><enddate>19690104</enddate><creator>Prichard, B. N. C.</creator><creator>Gillam, P. M. S.</creator><general>British Medical Journal Publishing Group</general><general>British Medical Association</general><general>BMJ Publishing Group LTD</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>19690104</creationdate><title>Treatment of Hypertension with Propranolol</title><author>Prichard, B. N. C. ; Gillam, P. M. S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b499t-26de9d12c2bd6c57fddaee222d17bd43464743b6dbf14c5863cb80564a3970373</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1969</creationdate><topic>Average age</topic><topic>Blood pressure</topic><topic>Blood Pressure - drug effects</topic><topic>Cardiac Output - drug effects</topic><topic>Cardiac output determination</topic><topic>Diuretics</topic><topic>Dosage</topic><topic>Female</topic><topic>Guanethidine - therapeutic use</topic><topic>Guanidines - therapeutic use</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Hypertension - drug therapy</topic><topic>Hypotension - chemically induced</topic><topic>Left ventricular hypertrophy</topic><topic>Male</topic><topic>Methyldopa - therapeutic use</topic><topic>Middle Aged</topic><topic>Papers and Originals</topic><topic>Physical Exertion</topic><topic>Physicians</topic><topic>Placebos</topic><topic>Posture</topic><topic>Pressoreceptors - physiology</topic><topic>Pressure pulses</topic><topic>Propranolol - administration & dosage</topic><topic>Propranolol - adverse effects</topic><topic>Propranolol - therapeutic use</topic><topic>Valsalva Maneuver</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Prichard, B. N. C.</creatorcontrib><creatorcontrib>Gillam, P. M. S.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BMJ</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Prichard, B. N. C.</au><au>Gillam, P. M. S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of Hypertension with Propranolol</atitle><jtitle>BMJ</jtitle><addtitle>Br Med J</addtitle><date>1969-01-04</date><risdate>1969</risdate><volume>1</volume><issue>5635</issue><spage>7</spage><epage>16</epage><pages>7-16</pages><issn>0007-1447</issn><issn>0959-8138</issn><eissn>1468-5833</eissn><abstract>When used in the treatment of hypertension propranolol is at least of similar potency to bethanidine, guanethidine, and methyldopa. Propranolol does not produce postural or exercise hypotension and it seems that it is often more acceptable to patients than conventional drugs. It usually produces the best control of the supine blood pressure. A series of 109 hypertensive patients was treated with propranolol; in nine the drug was withdrawn. In 92 of the patients a supine or standing blood pressure of 100 mm. Hg or less was achieved. Eighty of the patients had previously been treated with other potent drugs, and close comparisons and prolonged follow-up in 17 patients showed that diastolic pressures of 100 mm. Hg or less were achieved in more patients after propranolol than with guanethidine, bethanidine, or methyldopa. Sensitivity to propranolol varies widely, and dosage should be increased gradually. The hypotensive effect often takes six to eight weeks to reach its maximum. Propranolol reduces cardiac output but may also act by reducing the cardiac component of pressor stimuli; as a result the baroreceptors gradually regulate the blood pressure at a lower level. It is contraindicated in patients with obstructive airways disease or in uncompensated heart failure.</abstract><cop>England</cop><pub>British Medical Journal Publishing Group</pub><pmid>5761914</pmid><doi>10.1136/bmj.1.5635.7</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0007-1447 |
ispartof | BMJ, 1969-01, Vol.1 (5635), p.7-16 |
issn | 0007-1447 0959-8138 1468-5833 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1981816 |
source | MEDLINE; JSTOR Archive Collection A-Z Listing; PubMed Central |
subjects | Average age Blood pressure Blood Pressure - drug effects Cardiac Output - drug effects Cardiac output determination Diuretics Dosage Female Guanethidine - therapeutic use Guanidines - therapeutic use Humans Hypertension Hypertension - drug therapy Hypotension - chemically induced Left ventricular hypertrophy Male Methyldopa - therapeutic use Middle Aged Papers and Originals Physical Exertion Physicians Placebos Posture Pressoreceptors - physiology Pressure pulses Propranolol - administration & dosage Propranolol - adverse effects Propranolol - therapeutic use Valsalva Maneuver |
title | Treatment of Hypertension with Propranolol |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T13%3A45%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20Hypertension%20with%20Propranolol&rft.jtitle=BMJ&rft.au=Prichard,%20B.%20N.%20C.&rft.date=1969-01-04&rft.volume=1&rft.issue=5635&rft.spage=7&rft.epage=16&rft.pages=7-16&rft.issn=0007-1447&rft.eissn=1468-5833&rft_id=info:doi/10.1136/bmj.1.5635.7&rft_dat=%3Cjstor_pubme%3E20395359%3C/jstor_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1776251687&rft_id=info:pmid/5761914&rft_jstor_id=20395359&rfr_iscdi=true |